OX2 Therapeutics
Updated: December 16, 2025
Michael Olin - Chief Scientific Officer & Founder
Country: USA | Funding: $3.5M (+)
Founded: 2016
Website: https://ox2therapeutics.com/
OX2 Therapeutics is developing immunotherapy for the treatment of brain tumors based on scientific discoveries of the University of Minnesota. OX2 Therapeutics has developed a first-of-its-kind peptide that targets the immune checkpoint activation receptor CD200. The peptide activates the immune system through a mechanism that modulates the suppressive effects of the immune checkpoints CD200, PD-1/PD-L1 and CTLA4, enabling more potent antitumor response. CD200 is upregulated on tumor-associated vascular endothelial cells, creating an immunological barrier that inactivates T cells (cancer-fighting cells) as they attempt to penetrate the tumor environment. The company has received FDA clearance to conduct clinical trials of combination therapy for the treatment of high-grade glioblastoma, for which there is no curative therapy.
Founded: 2016
Website: https://ox2therapeutics.com/
OX2 Therapeutics is developing immunotherapy for the treatment of brain tumors based on scientific discoveries of the University of Minnesota. OX2 Therapeutics has developed a first-of-its-kind peptide that targets the immune checkpoint activation receptor CD200. The peptide activates the immune system through a mechanism that modulates the suppressive effects of the immune checkpoints CD200, PD-1/PD-L1 and CTLA4, enabling more potent antitumor response. CD200 is upregulated on tumor-associated vascular endothelial cells, creating an immunological barrier that inactivates T cells (cancer-fighting cells) as they attempt to penetrate the tumor environment. The company has received FDA clearance to conduct clinical trials of combination therapy for the treatment of high-grade glioblastoma, for which there is no curative therapy.
